The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Daniel Costin Danila
Honoraria - Angle; Astellas Pharma; AxImmune; Clovis Oncology; Pfizer; Pfizer
Consulting or Advisory Role - Angle; Astellas Pharma; AxImmune; Clovis Oncology; Pfizer; Sanador
Research Funding - Janssen Research & Development (Inst); Prostate Cancer Foundation
Patents, Royalties, Other Intellectual Property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
Travel, Accommodations, Expenses - American Austrian Open Medical Institute; Astellas Pharma; Genzyme; Janssen Scientific Affairs; Pfizer; Prostate Cancer Foundation
 
David Michael Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AZTherapies; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Fresenius Kabi; Janssen Oncology; Jazz Pharmaceuticals; Lilly; McGivney Global Advisors; Merck; Mirati Therapeutics; Pfizer; Sanofi; Sanofi/Regeneron; Seagen
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Leonard Joseph Appleman
Consulting or Advisory Role - AADi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Janssen Oncology; Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology (Inst)
Other Relationship - Pfizer
(OPTIONAL) Uncompensated Relationships - Exelixis
 
David William Pook
Honoraria - Bayer
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Nobuaki Matsubara
Honoraria - Bayer; Chugai Pharma (Inst); Janssen
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Takeda (Inst)
 
Tanya B. Dorff
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; AstraZeneca; Bayer; Exelixis; Janssen Oncology; Pfizer; Seagen
Research Funding - Pfizer (Inst)
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; BeiGene; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Myovant Sciences; Zymeworks
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer
Consulting or Advisory Role - AstraZeneca; BMS Korea; GI Innovation; Merck; MSD; Oscotec; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Exelixis; FORMA Therapeutics; GoodRx; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Miso Kim
Consulting or Advisory Role - Bristol-Myers Squibb/Ono Pharmaceutical; Ipsen; Merck; MSD; Novartis; Pfizer; Roche
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Imagion Biosystems
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer
 
Christopher Joseph Sumey
Consulting or Advisory Role - Bristol-Myers Squibb
 
Freda Cooner
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Mark Salvati
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Julia Stieglmaier
Employment - Amgen; Incyte (I)
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb (I); Celgene (I); Incyte (I)
Patents, Royalties, Other Intellectual Property - Amgen
 
William Kevin Kelly
Honoraria - Janssen Oncology
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Merck Sharp & Dohme